📊 $BLGO: The Math Doesn’t Lie - This Might Be the Most Undervalued Cleantech on the Market.

🤯 A Company With 4 Revenue-Generating Subsidiaries Trading at This $35 Million Market Cap Is Absurd. BioLargo $BLGO

💥 Yes, I put my money where my mouth is. I trust my DD - just added heavily in this region. 🎯

I’ve been here before. Different ticker, same setup. EXAS went 2,000% from where I bought on a crazy dip - I’m seeing the same pattern in $BLGO and I just added heavily.

Let’s be real about what just happened. Someone exited their position, fear cascaded, and retail panic did what it always does - handed shares from weak hands to strong ones. If you’ve been following BioLargo for any length of time, you’ve seen this movie before. And you know how it ends.

The fundamentals have not changed. Not even slightly. What HAS changed is the price - and that means the opportunity just got bigger.

\\---

The Market Cap Argument Is Absurd

Let’s put this in perspective. A 10X move from here represents a market cap of only \\\~$350 million dollars. For context, that is a rounding error for most mid-cap cleantech companies. BioLargo is not a shell, not a concept, not a whitepaper. It is a multi-subsidiary operating company with real contracts, real revenue, real technology, and real momentum across multiple verticals simultaneously.

The market simply hasn’t caught up yet. That’s the opportunity.

\\---

What’s Actually Happening Inside This Company Right Now

💧 AEC PFAS Water Treatment - The Crown Jewel

BioLargo’s Aqueous Electrostatic Concentrator (AEC) has been installed at a real municipal drinking water facility in Lake Stockholm, NJ. This isn’t a lab demo - it’s boots on the ground, treating real water for real communities. On top of that, the team achieved a greater than 90% reduction in energy use, which is the single biggest barrier to PFAS treatment scalability. The technology was featured in Chemical Engineering magazine. Aquatech - a globally recognized water technology company - signed an MOU with BioLargo to accelerate PFAS commercialization. The regulatory tailwind from EPA PFAS drinking water standards is enormous and only getting stronger.

🏭 BioLargo Engineering, Science & Technologies (BEST) - Revenue Engine

BEST is not waiting around. A $1.2 million contract was awarded in April 2026 to design a pilot-scale minerals processing facility. Engineering services revenue grew +98% in 2025. This subsidiary is profitable, cash-generating, and feeds directly into the broader IP commercialization pipeline. It also gives BioLargo operational credibility that pure-play IP companies simply don’t have.

🩹 Clyra Medical - MENA Expansion Underway

Clyra secured an exclusive distribution agreement for ViaCLYR™ across the Middle East and North Africa. This is a meaningful geographic expansion for a wound care product with demonstrated clinical efficacy. 2026 was flagged as a year of meaningful revenue contribution from Clyra — and the distribution deal puts that squarely in play.

🔋 BioLargo Energy — Battery JV in Motion

The battery technology joint venture is advancing toward commercialization. Energy storage is one of the hottest sectors on the planet right now. BioLargo has a seat at that table too.

\\---

The Big Picture

This is a company operating across PFAS water treatment, wound care, environmental engineering, and energy storage — four sectors with massive tailwinds, growing regulatory support, and surging institutional interest globally. The CEO has been transparent, the team has been executing, and the catalysts keep stacking.

Weak hands just gave you their shares. The question is whether you’re going to take them.

Do your own DD. Read the filings. Watch the CEO interviews. Understand what you own.

But if you’ve done that work already — you know what this is.

🙏 Not financial advice. Do your own due diligence.

\\#BLGO #BioLargo #cleantech #PFAS #watertreatment #undervalued #smallcap #investing